Skip to main content

SMMT Summit Therapeutics Inc.

Healthcare

17.59

Close 10/9

Open
17.36
High
17.62
Low
16.82
Prev close
17.17
Volume
5.7M
52W 12.07 29.23
Loading candles…

Is Summit Therapeutics Inc. a buy? Fundamentals and valuation first

As of 2026-10-09

Momentum: Good.

Momentum Good 60-day return is Top, but 240-day return is Average.
60-day return (%) 27.83 92th percentile Top
240-day return (%) -8.77 44th percentile Average
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 127,843,016 89th percentile Top
60-day annualized volatility (%) 69.82 70th percentile Average

Summit Therapeutics Inc. (SMMT) peers and tracking

Watchlist

This page refreshes daily after the close. Add Summit Therapeutics Inc. to your watchlist to track signal changes on your next visit.

Summit Therapeutics Inc. (SMMT) quant signal backtests

Market-wide momentum baseline

Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.43%, a 58.5% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

More history: Signals not active now

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

14 times historically; 60-day forward avg +10.21%, win rate 50%, beating the market by +2.11 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

33 times historically; 60-day forward avg +20.09%, win rate 63.6%, beating the market by +15.15 pts on average.

Continue researching Summit Therapeutics Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • The company has reported its financial statements in more than one currency, so margins, growth and valuation figures that would combine them are not computed.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.